Evidence map›Paper›PMID 36451823›Full record

ArticleFrontiers in immunology2022

Pilot genome-wide association study of antibody response to inactivated SARS-CoV-2 vaccines.

Ping Li, Dawei Shi, Wenlong Shen, Shu Shi, Xinjie Guo, Jia Li, Sihong Xu, Yan Zhang, Zhihu Zhao

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ping LiDepartment of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China.
Dawei ShiDivision II of In Vitro Diagnostics for Infectious Diseases, Institute for In Vitro Diagnostics Control, National Institutes for Food and Drug Control, Beijing, China.
Wenlong ShenDepartment of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China.
Shu ShiDepartment of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China.
Xinjie GuoDepartment of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China.
Jia LiDivision of Arboviral Vaccine, National Institutes for Food and Drug Control, Beijing, China.
Sihong XuDivision II of In Vitro Diagnostics for Infectious Diseases, Institute for In Vitro Diagnostics Control, National Institutes for Food and Drug Control, Beijing, China.
Yan ZhangDepartment of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China.
Zhihu ZhaoDepartment of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China.
National Institutes for Food and Drug Control · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccines are a key weapon against the COVID-19 pandemic caused by SARS-CoV-2. However, there are inter-individual differences in immune response to SARS-CoV-2 vaccines and genetic contributions to these differences have barely been investigated. Here, we performed genome-wide association study (GWAS) of antibody levels in 168 inactivated SARS-CoV-2 vaccine recipients. A total of 177 SNPs, corresponding to 41 independent loci, were identified to be associated with IgG, total antibodies or neutral antibodies. Specifically, the rs4543780, the intronic variant of FAM89A gene, was associated with total antibodies level and was annotated as a potential regulatory variant affecting gene expression of FAM89A, a biomarker differentiating bacterial from viral infections in febrile children. These findings might advance our knowledge of the molecular mechanisms driving immunity to SARS-CoV-2 vaccine.

Indexed as

COVID-19COVID-19 VaccinesAntibody FormationChildGenome-Wide Association StudyHumansPandemicsSARS-CoV-2COVID-19 VaccinesantibodyCOVID-19GWASSARS-CoV-2SNPvaccine

Identifiers

PMID36451823
PMCPMC9704361
OpenAlexW4309043397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.